Biosimilars | Access & Reimbursement | US/EU5 | 2018
Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra are available both in Europe and the United States, the level of their success can vary due to regional differences in the drivers and barriers to biosimilar uptake. As such, it is necessary for biosimilar developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilar uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose between multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilar discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
Key markets covered:
- France.
- Germany.
- Italy.
- Spain.
- United Kingdom.
- United States.
Key companies mentioned:
- Amgen.
- Boehringer Ingelheim.
- Celltrion.
- Eli Lilly.
- Hospira.
- Janssen.
- Johnson & Johnson.
- Merck & Co.
- Mundipharma.
- Mylan.
- Novartis.
- Pfizer.
- Roche.
- Samsung Bioepis.
- Sandoz.
- Sanofi.
- Teva.
Key drugs mentioned:
- Aranesp.
- Avastin.
- Basaglar.
- Benepali.
- Binocrit.
- Enbrel.
- Flixabi.
- Genotropin.
- Herceptin.
- Humira.
- Inflectra.
- Lantus.
- Neulasta.
- Neupogen.
- Nivestim.
- Omnitrope.
- Procrit/Epogen.
- Remicade.
- Remsima.
- Rituxan/MabThera.
- Truxima.
- Zarzio/Zarxio.
Related Market Assessment Reports
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
